Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,325 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,671 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06006286 | A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 26, 2024 | clinicaltrials |
| NCT01445275 | Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199 | withdrawn | — | 0 | Gynecologic Oncology GroupNETWORK | 1 | Aug 21, 2024 |
| clinicaltrials |
| NCT04205786 | Vitamin B12 for Aromatase Inhibitors Associated Musculoskeletal Symptoms in Breast Cancer | withdrawn | N/A | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT06216561 | Intraperitoneal LSTA1 in CRS-HIPEC | withdrawn | Phase 1 | 0 | University of California, San DiegoOTHER | 1 | Aug 20, 2024 | clinicaltrials |
| NCT05450393 | Data Collection of PillCamTM SB3 Capsule Endoscopy and Device-Assisted Enteroscopy Routine Care Procedures (GPS Study) | withdrawn | — | 0 | Medtronic - MITGINDUSTRY | 0 | Aug 19, 2024 | clinicaltrials |
| NCT06110598 | CAPEcitabine eXtension of Adjuvant Therapy for Pancreatic Adenocarcinoma: (CAPE-X) | withdrawn | Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT06007911 | Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia | withdrawn | Phase 1 | 0 | Medical College of WisconsinOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT05672342 | Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors | withdrawn | Early Phase 1 | 0 | City of Hope Medical CenterOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06337162 | Pre-Transplant INCBB099280 for Hepatocellular Carcinoma (HCC)(HCC) | withdrawn | Phase 1 | 0 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT01843868 | Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP | withdrawn | N/A | 0 | Australasian Leukaemia and Lymphoma GroupOTHER | 0 | Aug 7, 2024 | clinicaltrials |
| NCT03327064 | A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for Non-melanoma Skin Cancer | withdrawn | Phase 1 / Phase 2 | 0 | University of Alabama at BirminghamOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT05622591 | ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive AML(Pediatric AML) | withdrawn | Phase 1 | 0 | Elucida OncologyINDUSTRY | 0 | Aug 7, 2024 | clinicaltrials |
| NCT01239108 | Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory Leukemias | withdrawn | Phase 1 | 0 | Astex Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 2, 2024 | clinicaltrials |
| NCT05574504 | Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy | withdrawn | Phase 2 | 0 | AdventHealthOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT03150745 | Diagnosis of Cervical Lesions in Women With Unhealthy Looking Cervix | withdrawn | N/A | 0 | Assiut UniversityOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT03423264 | PROGRESS Trial - Prophylactic Gabapentin for Relief of Symptoms and Improved Swallowing | withdrawn | Phase 2 | 0 | University of ChicagoOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT04955938 | A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms | withdrawn | Phase 1 | 0 | University of ChicagoOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT06384820 | Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC) | withdrawn | Phase 2 | 0 | Regeneron PharmaceuticalsINDUSTRY | 0 | Jul 26, 2024 | clinicaltrials |
| NCT06084845 | Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer | withdrawn | Phase 2 | 0 | ECOG-ACRIN Cancer Research GroupNETWORK | 0 | Jul 25, 2024 | clinicaltrials |
| NCT02535078 | Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma | withdrawn | Phase 1 / Phase 2 | 0 | Immunocore LtdINDUSTRY | 1 | Jul 24, 2024 | clinicaltrials |
| NCT06398587 | Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma | withdrawn | Phase 2 | 0 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 19, 2024 | clinicaltrials |
| NCT06370871 | Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma | withdrawn | Phase 3 | 0 | Boehringer IngelheimINDUSTRY | 0 | Jul 17, 2024 | clinicaltrials |
| NCT05050305 | Marizomib Central Nervous System (CNS) | withdrawn | Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT05936229 | Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy | withdrawn | Phase 1 / Phase 2 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 12, 2024 | clinicaltrials |
| NCT05820763 | Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant | withdrawn | Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Jul 10, 2024 | clinicaltrials |
| NCT05364645 | Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer | withdrawn | Phase 2 | 0 | SWOG Cancer Research NetworkNETWORK | 1 | Jul 9, 2024 | clinicaltrials |
| NCT05738161 | Magrolimab in Combination With Cytotoxic Chemotherapy in Advanced Urothelial Carcinoma(MACOCUC-01) | withdrawn | Phase 1 | 0 | Insel Gruppe AG, University Hospital BernOTHER | 0 | Jul 5, 2024 | clinicaltrials |
| NCT05204160 | Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell Therapy | withdrawn | Phase 2 | 0 | Emory UniversityOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06357858 | ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck | withdrawn | Phase 1 | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT05545969 | Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma(Neo PeLeMM) | withdrawn | Phase 2 | 0 | Melanoma Institute AustraliaOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT04833959 | Pilot Study of 89-Zr Panitumumab in Pancreas Cancer | withdrawn | Phase 1 | 0 | Stanford UniversityOTHER | 1 | Jun 21, 2024 | clinicaltrials |
| NCT05740449 | HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies(HEM-iSMART A) | withdrawn | Phase 1 / Phase 2 | 0 | Princess Maxima Center for Pediatric OncologyOTHER | 1 | Jun 21, 2024 | clinicaltrials |
| NCT02840227 | The Effect of Combined General/Regional Anesthesia on Cancer Recurrence in Patients Having Lung Cancer Resections | withdrawn | N/A | 0 | The Cleveland ClinicOTHER | 1 | Jun 20, 2024 | clinicaltrials |
| NCT05567055 | Central Nervous System Efficacy of Capmatinib in NSCLC With Brain Metastases With cfDNA Positive MET Alterations | withdrawn | Phase 2 | 0 | Timothy Burns, MD, PHDOTHER | 0 | Jun 17, 2024 | clinicaltrials |
| NCT06337331 | Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant | withdrawn | Phase 2 | 0 | Northside Hospital, Inc.OTHER | 1 | Jun 14, 2024 | clinicaltrials |
| NCT05471401 | GI Organ Tracking Via Balloon Applicators | withdrawn | N/A | 0 | Washington University School of MedicineOTHER | 0 | Jun 13, 2024 | clinicaltrials |
| NCT04584775 | Implementing Acupuncture and Chinese Herbal Medicine Into Palliative Care | withdrawn | N/A | 0 | Medical University of GrazOTHER | 1 | Jun 12, 2024 | clinicaltrials |
| NCT05082493 | A Multicenter, Study of the Safety and Pharmacokinetics of Intravenously Infused Berubicin in Pediatric Patients With Progressive, Refractory, or Recurrent High Grade Gliomas | withdrawn | Phase 1 | 0 | WPD Pharmaceuticals Sp. z o.o.INDUSTRY | 0 | Jun 6, 2024 | clinicaltrials |
| NCT05572476 | Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer(LURBIMUNE) | withdrawn | Phase 2 | 0 | Institut BergoniéOTHER | 1 | Jun 5, 2024 | clinicaltrials |
| NCT06232707 | A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)(ALUMMINATE) | withdrawn | Phase 3 | 0 | CelgeneINDUSTRY | 27 | May 31, 2024 | clinicaltrials |
| NCT05568940 | Evaluating Tibolone Add-back in Patients With Endometriosis and Fibroids(eTAPE) | withdrawn | — | 0 | McGill University Health Centre/Research Institute of the McGill University Health CentreOTHER | 1 | May 30, 2024 | clinicaltrials |
| NCT05309018 | Implantation of an Advanced Practice Nurse in the Complex Care Pathway of Patients With AML(LAMIPA) | withdrawn | — | 0 | Centre Hospitalier Régional Metz-ThionvilleOTHER | 0 | May 23, 2024 | clinicaltrials |
| NCT05411107 | Oral Iloprost for the Prevention of Lung Cancer In Former Smokers | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | May 17, 2024 | clinicaltrials |
| NCT06210750 | Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | May 17, 2024 | clinicaltrials |
| NCT06057636 | Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study | withdrawn | N/A | 0 | The University of Tennessee, KnoxvilleOTHER | 1 | May 10, 2024 | clinicaltrials |
| NCT01622764 | 89Zr-RO5323441 PET Imaging in Glioblastoma | withdrawn | Phase 2 | 0 | University Medical Center GroningenOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT05073172 | StrataXRT for the Prevention and Treatment of Radiation Dermatitis in Breast Cancer or Head and Neck Cancer Patients | withdrawn | N/A | 0 | OHSU Knight Cancer InstituteOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT05403580 | Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Patients With Advanced Cancer | withdrawn | Phase 3 | 0 | Mayo ClinicOTHER | 0 | May 6, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Aug 26, 2024source: clinicaltrials